Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antibody treatment protects monkeys from Hendra virus disease

20.10.2011
NIH-supported group exploring whether protection extends to Nipah virus disease

A human antibody given to monkeys infected with the deadly Hendra virus completely protected them from disease, according to a study published by National Institutes of Health (NIH) scientists and their collaborators.


This is the Hendra virus.
Credit: Courtesy Dr. Alex Hyatt, AAHL

Hendra and the closely related Nipah virus, both rare viruses that are part of the NIH biodefense research program, target the lungs and brain and have human case fatality rates of 60 percent and more than 75 percent, respectively. These diseases in monkeys mirror what happens in humans, and the study results are cause for hope that the antibody, named m102.4, ultimately may be developed into a possible treatment for people who become infected with these viruses.

In May 2010, shortly after the NIH study in monkeys successfully concluded, Australian health officials requested m102.4 for emergency use in a woman and her 12-year-old daughter. They had been exposed to Hendra virus from an ill horse that ultimately was euthanized. Both the woman and child survived and showed no side effects from the treatment.

"This is an important research advance that illustrates how scientific discoveries emerge through a steady stepwise process, and how our investment in research on countermeasures for biodefense and emerging infectious diseases can help global preparedness efforts," said Anthony S. Fauci, M.D., director of the NIH's National Institute of Allergy and Infectious Diseases (NIAID).

Hendra virus emerged in 1994 in Australia and primarily affects horses, which can spread the disease to humans. No person-to-person transmission of Hendra has been reported. Nipah virus emerged in 1998 in Malaysia, and also has been found in Bangladesh and India. Nipah appears to infect humans more easily than Hendra and can be transmitted from person to person.

The NIAID-supported study, which appears online in Science Translational Medicine, involved infecting 14 African green monkeys with a lethal dose of Hendra virus. Twelve of the monkeys then received two treatments with m102.4, one either at 10, 24, or 72 hours after being infected, and another 48 hours later. All 12 monkeys treated with the antibody survived. The two untreated control monkeys died eight days after being infected.

The findings are the result of a series of studies carried out by different research laboratories. A group from NIH's National Cancer Institute and the Uniformed Services University of the Health Sciences (USUHS) discovered m102.4 in 2006 and developed the antibody for use in laboratory research. USUHS and Australian collaborators then developed an animal study model of m102.4 in ferrets infected with Nipah virus; the University of Texas Medical Branch and USUHS developed a monkey study model of Hendra and Nipah infection; and together with investigators from Boston University and NIAID's Rocky Mountain Laboratories (RML) designed and carried out the antibody trial in biosafety level-4 (BSL-4) laboratory space at RML. Because the Hendra and Nipah viruses are so deadly and there is no licensed vaccine or treatment for either of them, both viruses must be studied in maximum-containment BSL-4 laboratories.

The World Health Organization reports 475 human cases of Nipah through 2008, with 251 deaths. Through the same period, there have been seven human Hendra cases with four fatalities. There also have been many horse fatalities. In their study, the scientists cite a handful of other outbreaks of Hendra virus in horses since 2008. Since June 2011, there have been 18 outbreaks in Australia, primarily in Queensland and New South Wales, with the latest reported Oct. 10.

Both viruses are spread by fruit bats, commonly known as flying foxes, which are reservoirs for these viruses. The fruit bats, which are resistant to the diseases, are found primarily in Australia but have been found as far west as Africa, north to India and Pakistan, and east to the Philippines.

Additional studies on m102.4 as a possible treatment and as a preventive vaccine for Nipah and Hendra virus infections are being planned.

###

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Reference: K Bossart et al. A neutralizing human monoclonal antibody protects African Green monkeys from Hendra virus challenge. Science Translational Medicine. DOI: 10.1126/scitranslmed.3002901 (2011).

--------------------------------------------------------------------------------

Ken Pekoc | EurekAlert!
Further information:
http://www.nih.gov

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>